NCT06298357 2026-03-18
Virtual Reality Gaming for Exercise and Mindfulness Among Pediatric Cancer Rehabilitation
University of Alabama at Birmingham
Phase 1 Completed
Clinical Trials
753 trialsNCT02423057 2026-03-06
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03964233 2026-02-18
A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)
Boehringer Ingelheim
Phase 1 Completed
NCT01534598 2026-02-10
FdCyd and THU for Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02952248 2026-01-27
A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT01445509 2026-01-15
Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02275910 2025-12-16
Phase 1 Study of E7090 in Subjects With Solid Tumor
Eisai Inc.
Phase 1 Completed
NCT05165433 2025-12-16
FORTIFY
Akamis Bio
Phase 1 Completed
NCT03449381 2025-11-26
This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
Phase 1 Completed
NCT05586321 2025-11-24
Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors
Genmab
Phase 1 Completed
NCT03486301 2025-11-12
EIK1001
Eikon Therapeutics
Phase 1 Completed
NCT04196530 2025-11-12
EIK1001
Eikon Therapeutics
Phase 1 Completed
NCT04840394 2025-11-12
Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Eikon Therapeutics
Phase 1 Completed
NCT06644170 2025-10-14
A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer
University of Washington
Phase 1 Completed
NCT05514444 2025-10-09
MK-4464-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT03564691 2025-10-07
MK-4830-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT03972150 2025-10-06
A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT02674152 2025-10-01
Dose Finding Study of BI 836880 in Patients With Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT02689505 2025-10-01
Weekly BI 836880 in Patients With Advanced Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT06296056 2025-10-01
SDH-Combi
Seoul Hospital
Phase 1 Completed
NCT06098651 2025-09-29
A Study of DCR-STAT3 in Adults With Solid Tumors
Novo Nordisk A/S
Phase 1 Completed
NCT04710043 2025-09-25
Dose Escalation Trial of BNT152+153 in Patients With Cancer
BioNTech SE
Phase 1 Completed
NCT05501821 2025-09-25
Study of KBA1412 in Participants With Advanced Solid Malignant Tumors
Kling Biotherapeutics B.V.
Phase 1 Completed
NCT03036228 2025-09-09
MASTIFF
Thomas Helleday Foundation
Phase 1 Completed
NCT07138352 2025-08-22
XS003-14
Xspray Pharma AB
Phase 1 Completed
NCT07138378 2025-08-22
XS003-11
Xspray Pharma AB
Phase 1 Completed
NCT04147234 2025-08-19
A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)
Boehringer Ingelheim
Phase 1 Completed
NCT03324113 2025-08-05
Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors
Sanofi
Phase 1 Completed
NCT03059823 2025-08-03
A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors
Incyte Corporation
Phase 1 Completed
NCT02775292 2025-07-30
NYM
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT03307629 2025-07-29
Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer
Noxopharm Limited
Phase 1 Completed
NCT05028556 2025-07-20
A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors
Wuhan YZY Biopharma Co., Ltd.
Phase 1 Completed
NCT04501744 2025-07-17
A Study of M701 (EpCAM and CD3) in Malignant Ascites
Wuhan YZY Biopharma Co., Ltd.
Phase 1 Completed
NCT02123823 2025-07-15
BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT01317420 2025-07-11
Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types
Boehringer Ingelheim
Phase 1 Completed
NCT04730843 2025-06-23
A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors
Elpiscience Biopharma, Ltd.
Phase 1 Completed
NCT04991506 2025-06-23
A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors
Elpiscience Biopharma, Ltd.
Phase 1 Completed
NCT02145741 2025-06-19
Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT03547037 2025-04-28
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers
Janssen Pharmaceutical K.K.
Phase 1 Completed
NCT03260322 2025-04-24
A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Astellas Pharma Inc
Phase 1 Completed
NCT03724890 2025-04-10
Study of Avelumab-M3814 Combinations
EMD Serono
Phase 1 Completed
NCT04236414 2025-04-04
Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours
AstraZeneca
Phase 1 Completed
NCT05584111 2025-03-26
Oral Administration of STC-15 in Subjects With Advanced Malignancies
STORM Therapeutics LTD
Phase 1 Completed
NCT05043714 2025-03-24
NEBULA
Akamis Bio
Phase 1 Completed
NCT01836705 2025-03-05
Effect of SAR302503 on ECG Activity in Patients With Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT04728334 2025-03-03
A Phase 1 Dose Escalation and Expansion Study of AK117
Akeso
Phase 1 Completed
NCT05940571 2025-03-03
First Phase Clinical Trial of Single Agent MBF-362 in Solid Tumors
Medibiofarma S.L.
Phase 1 Completed
NCT04047290 2025-02-28
A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors
Akeso
Phase 1 Completed
NCT02966548 2025-02-17
Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT02070549 2025-02-13
Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction
National Cancer Institute (NCI)
Phase 1 Completed